Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
January 09 2020 - 8:30AM
Business Wire
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the
company has licensed The Rockefeller University’s portfolio of
broadly neutralizing antibodies (bNAbs) against HIV, including the
two clinical-stage agents 3BNC117 and 10-1074. These
investigational agents have potential for use in HIV long-acting
therapies for treatment and prevention, as well as cure
strategies.
HIV bNAbs are a class of immunotherapy agents that were
originally derived from HIV-infected individuals with a strong
anti-HIV immunologic response and were designed to target HIV,
particularly originating from the latent viral reservoir. Initial
pre-clinical and clinical research has shown that HIV bNAbs can
produce an enhanced, prolonged immune response to HIV, representing
a promising new approach for HIV treatment or prevention in
combination with other long-acting agents, or prolonged virologic
remission in the absence of antiretroviral use. This licensing
agreement provides an additional pathway for innovations in
Gilead’s HIV pipeline in areas of evolving and unmet medical
need.
“The Rockefeller University’s broadly neutralizing HIV
antibodies are well studied and have shown exceptional promise in
early clinical trials,” said Diana Brainard, MD, Senior Vice
President, HIV and Emerging Viruses, Gilead Sciences. “By
harnessing the body’s own immune system against HIV, we seek to
continue driving scientific innovation that will transform care and
improve overall outcomes for all people living with HIV.”
“Our scientists have amassed an extensive body of research
showing that neutralizing antibodies have the potential to
transform HIV therapy for many people living with the disease,”
said Jeanne Farrell, PhD, Associate Vice President for Technology
Advancement at The Rockefeller University. “We are committed to
ensuring that this and other promising discoveries realize their
promise to impact healthcare, by partnering with commercial
stewards capable of advancing academic programs into potential
future products that may benefit patients.”
Under the agreement, Gilead acquires exclusive global licenses
to develop and commercialize Rockefeller’s full portfolio of HIV
bNAbs. Rockefeller will receive an upfront payment and is eligible
to receive cumulative milestone payments, as well as royalties on
net sales. Additionally, Rockefeller will retain rights to perform
non-clinical and early-stage clinical research on the portfolio of
HIV antibodies.
Antibodies 3BNC117 and 10-1074 are investigational therapies and
are not approved by any regulatory body globally; their safety and
efficacy have not been established. There is no cure for HIV or
AIDS.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more than 30 years, Gilead has been a leading innovator in
the field of HIV, driving advances in treatment, prevention,
testing and linkage to care, and cure research. Today, it is
estimated that more than 12 million people living with HIV globally
receive antiretroviral therapy provided by Gilead or one of the
company’s manufacturing partners.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that the parties may not realize the potential
benefits of this collaboration. It is possible that Gilead may make
a strategic decision to discontinue development of 3BNC117, 10-1074
and other HIV bNAbs if, for example, Gilead believes
commercialization will be difficult relative to other opportunities
in its pipeline. As a result, these HIV bNAbs may never be
successfully commercialized. All statements other than statements
of historical fact are statements that could be deemed
forward-looking statements. These risks, uncertainties and other
factors could cause actual results to differ materially from those
referred to in the forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. These
and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2019, as
filed with the U.S. Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to Gilead, and Gilead assumes no obligation to update any
such forward-looking statements.
Gilead and Gilead logo are trademarks of Gilead
Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200109005277/en/
Douglas Maffei, Ph.D., Investors (650) 522-2739
Ryan McKeel, Media (650) 377-3548
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024